The MUC1-ST/Siglec-9 innate check point axis in cancer: prevalence, prognostic significance and potential therapeutics.
Lead Research Organisation:
King's College London
Department Name: Cancer Studies
Abstract
Virtually all proteins carried on the surface of cells are decorated with sugars; these combined structures are known as glycoproteins. These sugars, or glycans, are fundamental to the function of the protein and are involved in cell:cell and cell:environment interactions. Importantly the sugars on these glycoproteins change as cancers develop and so, in cancer, the glycoproteins can interact with a new set of proteins and cells. We have previously shown that one particular glycoprotein, MUC1, expressed by breast cancers carries aberrant glycans that allow it to bind to specific immune cells, called monocytes and macrophages that infiltrate the tumour. Once the binding takes place the monocytes and macrophages change: the monocytes secrete factors that induce tumour growth and recruit more immune cells, and the macrophages become "tumour-associated macrophages" a type of cell that is associated with invasion and a poor prognosis.
In this project we plan to:
a) Determine how common these particular monocytes and macrophages are in breast cancer and to confirm that they are associated with a particular glycoform of MUC1.
b) Determine if the genes expressed by these macrophages induced by MUC1 is associated with prognosis.
c) Determine if inhibiting the interaction between MUC1 and the monocytes and macrophages can be used as a potential therapy for breast and other cancer patients. The interaction of MUC1 and the receptor on monocytes and macrophages acts as a "checkpoint" to inhibit the innate immune response. We hypothesize that blocking the interaction should release the brakes and allow for the immune system to recognise the tumour.
We plan to use of series of in vitro techniques to address these aims and our results should pave the way for preclinical testing of this new therapeutic approach.
In this project we plan to:
a) Determine how common these particular monocytes and macrophages are in breast cancer and to confirm that they are associated with a particular glycoform of MUC1.
b) Determine if the genes expressed by these macrophages induced by MUC1 is associated with prognosis.
c) Determine if inhibiting the interaction between MUC1 and the monocytes and macrophages can be used as a potential therapy for breast and other cancer patients. The interaction of MUC1 and the receptor on monocytes and macrophages acts as a "checkpoint" to inhibit the innate immune response. We hypothesize that blocking the interaction should release the brakes and allow for the immune system to recognise the tumour.
We plan to use of series of in vitro techniques to address these aims and our results should pave the way for preclinical testing of this new therapeutic approach.
Technical Summary
Tumour-associated macrophages are some of the most abundant immune cells found in tumours, their presence correlating with metastasis and poor prognosis. Changes in the post-translational modification glycosylation, is a hallmark of cancer and the glycosylation of MUC1 is dramatically altered in breast cancer. We have shown that a tumour-associated glycoform of MUC1 (MUC1-ST) binds to the lectin Siglec-9 expressed by monocytes and macrophages. This interaction results in the release of factors associated with tumour growth, modulation of the microenvironment and the induction of a tumour-associated macrophage (TAM) phenotype.
In this project we will confirm our in vitro data in vivo using primary breast cancers, define the transcriptome of the MUC1-ST induced macrophages and apply it to public databases to determine prognostic significance, and investigate therapeutic applications of blocking the MUC1-ST/Siglec-9 interaction using human in vitro models
We will phenotype macrophages infiltrating into breast cancer by 1) immunohistochemistry and RNAscope 2) flow cytometric analysis, and correlate this with the MUC1 glycoform (MUC1-ST) that binds Siglec-9. Using matched sera and tumour samples we will also determine if there is a correlation between MUC1-ST expressed by the tumours and the presence of factors secreted by myeloid cells after binding to MUC1-ST.
The transcriptome of macrophages differentiated from monocytes by MUC1-ST will be determined by RNAseq allowing us to develop a 'MUC1-ST macrophage' signature, which we will apply to large tumour datasets to understand the impact of these cells on disease.
We will also study the therapeutic potential of using antibodies to Siglec-9 to block the migration of labelled monocytes induced by MUC1-ST educated monocytes using in vitro assays and an organotypic breast cancer culture model. The effect on angiogenesis will also be investigated in vitro.
In this project we will confirm our in vitro data in vivo using primary breast cancers, define the transcriptome of the MUC1-ST induced macrophages and apply it to public databases to determine prognostic significance, and investigate therapeutic applications of blocking the MUC1-ST/Siglec-9 interaction using human in vitro models
We will phenotype macrophages infiltrating into breast cancer by 1) immunohistochemistry and RNAscope 2) flow cytometric analysis, and correlate this with the MUC1 glycoform (MUC1-ST) that binds Siglec-9. Using matched sera and tumour samples we will also determine if there is a correlation between MUC1-ST expressed by the tumours and the presence of factors secreted by myeloid cells after binding to MUC1-ST.
The transcriptome of macrophages differentiated from monocytes by MUC1-ST will be determined by RNAseq allowing us to develop a 'MUC1-ST macrophage' signature, which we will apply to large tumour datasets to understand the impact of these cells on disease.
We will also study the therapeutic potential of using antibodies to Siglec-9 to block the migration of labelled monocytes induced by MUC1-ST educated monocytes using in vitro assays and an organotypic breast cancer culture model. The effect on angiogenesis will also be investigated in vitro.
Planned Impact
This research will further our understanding of an entirely novel mechanism used by tumours to modulate their microenvironment and evade the host immune response. This may lead to new therapeutic approaches for the treatment of breast and other cancers. The importance of glycobiology in research is not well recognised in the UK compared to other countries, especially the US, where considerable funding streams are dedicated to this field. The project will raise the profile of glycobiology both nationally and internationally.
The beneficiaries of this research fall into the following categories:
1. Contribution to the nations health: The research has high potential to lead to a new therapeutic approach for the treatment of breast and other cancers. The proposal includes ex vivo work to determine the therapeutic potential of antibodies that prevent the interaction that leads to immune suppression. This will generate important preclinical data which will inform further work with animal models and, ultimately, clinical trials.
2. Clinicians will benefit from having additional therapeutic options to recommend to their patients.
3. Fostering the global economy: King's College London has filed a patent application on the research we performed leading up to this proposal (application number of GB1611535.4, entitled "Methods and Compositions for Treating Cancer with Siglec-9 Activity Modulators", filing date 1 July 2016). King's have licensed the rights under this patent to a company. The Siglec family of lectins have been described as the checkpoint of the innate immune system in ours and others work. Adaptive Immune Checkpoint Inhibitors are estimated to be a multi-billion dollar market over the coming decade. During the period 2015 - 2025, forecast suggests that the market will witness an annualized growth rate of 27.7% (Roots Analysis, Business Research and Consulting). Our research will provide further evidence that Siglecs, in particular Siglec-9, can act as innate immune checkpoints and therefore be excellent immunotherapeutic targets.
4. Public engagement including patients and young people: We feel patients benefit from a greater understanding of their disease and we hope to inspire young people giving them an interest in science and how it can be translated into benefits for society.
5. Academics within King's College and Leeds University, and the national and international academic community will benefit from the research. This has been discussed in detail in the academic beneficiary section.
Timescale:
Short term
Academics and young people should benefit from the research being conducting during at least year 2 and 3 of the project
Longer term:
Contribution to the nation's health: The idea of blocking interactions to enhance naturally occurring adaptive neoantigen immune responses is an idea that is moving fast in oncology as seen with the relatively rapid introduction of immune checkpoint inhibitors as therapeutic options for multiple cancers. It is hoped that clinical trials to block Siglec-9/MUC1 interactions as a single therapy and in combination with other agents will enter clinical trials in five years.
Fostering the global economy: This will happen within 10 years if the clinical trials are positive.
The beneficiaries of this research fall into the following categories:
1. Contribution to the nations health: The research has high potential to lead to a new therapeutic approach for the treatment of breast and other cancers. The proposal includes ex vivo work to determine the therapeutic potential of antibodies that prevent the interaction that leads to immune suppression. This will generate important preclinical data which will inform further work with animal models and, ultimately, clinical trials.
2. Clinicians will benefit from having additional therapeutic options to recommend to their patients.
3. Fostering the global economy: King's College London has filed a patent application on the research we performed leading up to this proposal (application number of GB1611535.4, entitled "Methods and Compositions for Treating Cancer with Siglec-9 Activity Modulators", filing date 1 July 2016). King's have licensed the rights under this patent to a company. The Siglec family of lectins have been described as the checkpoint of the innate immune system in ours and others work. Adaptive Immune Checkpoint Inhibitors are estimated to be a multi-billion dollar market over the coming decade. During the period 2015 - 2025, forecast suggests that the market will witness an annualized growth rate of 27.7% (Roots Analysis, Business Research and Consulting). Our research will provide further evidence that Siglecs, in particular Siglec-9, can act as innate immune checkpoints and therefore be excellent immunotherapeutic targets.
4. Public engagement including patients and young people: We feel patients benefit from a greater understanding of their disease and we hope to inspire young people giving them an interest in science and how it can be translated into benefits for society.
5. Academics within King's College and Leeds University, and the national and international academic community will benefit from the research. This has been discussed in detail in the academic beneficiary section.
Timescale:
Short term
Academics and young people should benefit from the research being conducting during at least year 2 and 3 of the project
Longer term:
Contribution to the nation's health: The idea of blocking interactions to enhance naturally occurring adaptive neoantigen immune responses is an idea that is moving fast in oncology as seen with the relatively rapid introduction of immune checkpoint inhibitors as therapeutic options for multiple cancers. It is hoped that clinical trials to block Siglec-9/MUC1 interactions as a single therapy and in combination with other agents will enter clinical trials in five years.
Fostering the global economy: This will happen within 10 years if the clinical trials are positive.
Publications
Beatson R
(2020)
Cancer-associated hypersialylated MUC1 drives the differentiation of human monocytes into macrophages with a pathogenic phenotype.
in Communications biology
Beatson RE
(2021)
TGF-ß1 potentiates V?9Vd2 T cell adoptive immunotherapy of cancer.
in Cell reports. Medicine
Burchell JM
(2018)
O-linked mucin-type glycosylation in breast cancer.
in Biochemical Society transactions
Ceeraz S
(2021)
Harnessing CD8+CD28- Regulatory T Cells as a Tool to Treat Autoimmune Disease.
in Cells
Deng J
(2023)
The role of TXNIP in cancer: a fine balance between redox, metabolic, and immunological tumor control.
in British journal of cancer
Lynham S
(2021)
Identification of chlorophyll a-b binding protein AB96 as a novel TGFß1 neutralizing agent.
in Scientific reports
Parente-Pereira AC
(2022)
Generation and application of TGFß-educated human V?9Vd2 T cells.
in STAR protocols
Sletmoen M
(2018)
Tn and STn are members of a family of carbohydrate tumor antigens that possess carbohydrate-carbohydrate interactions.
in Glycobiology
Tajadura-Ortega V
(2021)
O-linked mucin-type glycosylation regulates the transcriptional programme downstream of EGFR
in Glycobiology
Title | Breast Cancer Scarves |
Description | Working with an artist, Merlin Strangeway, we held a workshop for breast cancer patients. After hearing talks about the research the participants painted abstract images of cancer cells and immune cells. These were printed onto silk scarves. |
Type Of Art | Artwork |
Year Produced | 2019 |
Impact | The scarves were given to the patients and increased their understanding of our MRC funded research |
Title | Transcription profiling by RNAseq of MUC1-ST induced macrophages |
Description | Monocytes from three donors were isolated. Matched M-CSF and MUC1-ST monocyte-derived macrophages were cultured as described. Cells were harvested and FACS sorted (BD FACSAria II Cell Sorter) for live cells after staining with a live/dead dye (ThermoFisher; L23102). Total RNA was isolated from the sorted live cells using the RNeasy Mini Kit (Qiagen; 74104) with DNAse treatment (Sigma; DN25). RNA was quantitated using the Qubit system and the RIN score was assessed using an Agilent bioanalyser 2100 (Agilent RNA 6000 Nano Kit). All samples in this study had RIN scores of 10. PolyA isolation and library preparation was performed using SureSelect Strand Specific RNA-Seq Library Preparation kit (G9691B) on 335 ng of RNA per samples. Samples were run on the Illumina platform (HiSeq2500 Rapid) for 25 cycles. All data are deposited in GEO, reference GSE150613. |
Type Of Material | Database/Collection of data |
Year Produced | 2020 |
Provided To Others? | Yes |
Impact | Impact is unknown at present |
URL | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150613 |
Description | Collaboration with a joint PhD studentship from CRUK |
Organisation | Francis Crick Institute |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | This is a collaboration on a PhD studentship. We will be providing the tissue and CyTOF facilities. |
Collaborator Contribution | This is a CRUK funded studentship through the City of London Major Centre's PhD training programme. The supervisors are Ben Schmann and Oliver Pearce. |
Impact | This is a multi-disciplinary collaboration involving glyco-biologist (Oliver Pearce, Joy Burchell and Richard Beatson) and a glyco-chemist (Ben Schumann) |
Start Year | 2019 |
Description | Commercial collaboration |
Organisation | Palleon Pharmaceuticals Inc |
Country | United States |
Sector | Private |
PI Contribution | Collaboration with the US company Palleon Pharmaceuticals on the interaction of MUC1-ST with Siglec-9. We provided Palleon with some of our data on this interaction and gave advice in the area of MUC1-ST and the tumour micro-environment, |
Collaborator Contribution | Palleon worked on a fusion protein of sialidase linked to IgG. The aim is to remove sialic acid from the tumours and therefore stop interactions with Siglecs. They are expected to enter phase 1 trails in the first quarter of 2022 |
Impact | Our collaboration and that of other researchers has lead to Palleon being able to enter clinical trials in the near future. |
Start Year | 2016 |
Description | Commercial collaboration, Boehringer-Ingelheim |
Organisation | Boehringer Ingelheim |
Country | Germany |
Sector | Private |
PI Contribution | The original data that shows that MUC1-ST can induce a phenotypically distinct macrophage (Beatson et al al 2020) was used as a basis to look at these macrophages in IPF. Richard Beatson, Joanna Porter and myself are now in consultation with BI to set up a project to be carried out at UCL. |
Collaborator Contribution | BI will be providing research funding to the lab where Dr Beatson now works (I am now Professor Emeritus at King's). The contract has not been finalised yet. |
Impact | Too early for outcomes as still at the negotiation stage |
Start Year | 2022 |
Description | Discuss on mucin involvement in fibrosis |
Organisation | University College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Discussions with Prof Joanna Porter on potential experimental collaborations and grant applications. We have expertise on siglec interactions with mucins. |
Collaborator Contribution | Expertise in fibrosis |
Impact | The collaboration in multidisciplinary, the clinical expertise coming from Prof Porter and the siglec expertise from my lab. |
Start Year | 2019 |
Description | Experssion of MUC1-ST on exosomes |
Organisation | King's College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Preliminary experiments were conducted to establish if MUC1-ST, which binds to Siglec-9, could be found on exosomes. We provided the antibodues to determine the expression of MUC1-ST |
Collaborator Contribution | The Ng lab isolated the exosomes and carried out the dot blots. The results showed that MUC1-ST could be found on exosomes from patients with a high risk of developing lung cancer. |
Impact | Data used in a grant application to CRUK. |
Start Year | 2018 |
Description | CRUK Centre talk |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Professional Practitioners |
Results and Impact | This was a talk by Dr Richard Beatson to the members of the CRUK Centre. Numerous questions were asked about the research indicating engagement and a high level of interest. |
Year(s) Of Engagement Activity | 2020 |
Description | Charity voluteer workers |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Supporters |
Results and Impact | Lay talk to the volunteers followed by visit to the lab and demonstration of experiments. The feedback was very positive with the volunteers saying they have gained a good understanding of our research. They were particularly taken with the cost of equipment. |
Year(s) Of Engagement Activity | 2017 |
Description | Invited talk at International Meeting, PEGS Europe, Lisbon, Portugal |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | This was an invited talk to an International audience. After the talk I had further interactions with Biotech companies and was told that glycosylation was finally being recognised as being important in cancer and immunology. |
Year(s) Of Engagement Activity | 2019 |
URL | https://www.pegsummiteurope.com |
Description | K+ Speed Science Event |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | 10 Year 12 students (aged 16-17), who have not yet applied to university, took part in the speed science event at the end of several days experience at King's College London. |
Year(s) Of Engagement Activity | 2019 |
Description | Patient group workshop " Discover Science through Art" |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | This activity was to relate our MRC funded research to patients through art. After describing our work and hosting a lab visit the patients were taught to express their understanding of the research in art. The designs they achieved were then printed into scarves that each patients could keep. The patients really enjoyed the workshop and the interaction with the scientist. To quote one patient " I just wanted to reiterate how much I enjoyed Tuesday's workshop, I absolutely believe that it's such a great thg for both patients and researchers to have more interaction with each other" Moreover this workshop really allowed patients to understand our research as exemplified by the quote 'Cells are so influenced by the environment, aren't they?' We had planned to continue these workshops into 2020 but the Covid-19 pandemic inhibited this. As an alternative we are in the process of developing a whiteboard video describing our research that will be loaded onto YouTube. |
Year(s) Of Engagement Activity | 2019 |
URL | https://twitter.com/SweetBiology |
Description | Patient involvement via talk and art |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | This was a workshop where breast cancer patients were shown around the lab, given a lay talk about the research and then were engaged in painting activities. They were asked to paint cells and cancer cells in an abstract way and to put into painting their feelings about the disease. This was led by an artist, Merlin Strangeway. This occurred in December 2019 and further events were planned but these had to be cancelled due to Covid. |
Year(s) Of Engagement Activity | 2019 |
Description | QMUL (Bart's Cancer Institute Seminar Series) Titled "Sialic acids as innate immune activators; balancing self and non-self to repair or react" |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Increased the awareness of our research funded by the MRC. |
Year(s) Of Engagement Activity | 2019 |
Description | Symposium, talked entitled "MUC1 carrying sialylated core 1 glycans and tumour associated macrophages; mechanism, phenotype, prevalence and impact" |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Biomedical Research Centre at Guy's and St Thomas' symposium on RNAseq and single cell RNAseq. Richard Beatson presented our work on RMNAseq of MUC1-ST generated macrophages. The talk generated further interest in the BRC facility. |
Year(s) Of Engagement Activity | 2019 |
URL | http://www.guysandstthomasbrc.nihr.ac.uk/research-platforms/genomics/ |
Description | Talk at meeting organised by UK Therapeutic Cancer Prevention Network (UKTCPN) and the International Cancer Prevention Society (ICAPS) Titled: "Tumour Immuno-Modulation by MUC1 in Breast Cancers" |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Talk generated considerable interest and resulted in a further invitation to speak at Queen Mary University of London. |
Year(s) Of Engagement Activity | 2019 |
Description | Talk to South East London Consumer Research Panel (SELCRP) by Dr Richard Beatson |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Communicating our research to this panel. |
Year(s) Of Engagement Activity | 2020 |
Description | Talk to a Commercial Company, Palleon |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | This was a talk to Palleon Pharmaceuticals to describe our recent paper published in Communications Biology. This company's focus is on the Glyco-immune checkpoint and they are developing agents to prevent siglec-ligand binding. |
Year(s) Of Engagement Activity | 2020 |
URL | https://palleonpharma.com |
Description | Talk to year 1 children |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | A talk to year 1 children describing very basic immunology |
Year(s) Of Engagement Activity | 2021 |
Description | The immune-mediated micro-environmental effects of MUC1 carrying sialylated core 1 glycans. Invited talk at Mucins in Health and Disease, Cambridge, UK |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Around 85 academics and students attended the International Meeting on Mucins in Health and Disease and a 30min invited talk was presented. |
Year(s) Of Engagement Activity | 2019 |
Description | Tissue web site entry |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | This was describing our use of tissue from the Tissue Directory and Coordination Centre. |
Year(s) Of Engagement Activity | 2020 |
URL | https://biobankinguk.org/advancing-our-understanding-of-breast-cancer/ |
Description | Twitter Page |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Lab Twitter entitled Sweet Biology. We are currently trying to increase our Twitter presence. We now have 245 following and 117 followers. |
Year(s) Of Engagement Activity | 2019,2020,2021,2022 |
URL | https://twitter.com/SweetBiology |
Description | Video describing our research funded by this award |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | A video was made describing the research funded by the grant. It used a "white board" format and was posted on Vimeo and YouTube. Only the Vimeo address would be accepted in the URL box but the video is also on You tube: https://www.youtube.com/watch?v=ntYPmYF5-iY |
Year(s) Of Engagement Activity | 2020 |
URL | https://vimeo.com/545423931 |
Description | Visit of CRUK donors |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Visit by donors to CRUK. Our MRC funded research was describe by myself and the members of the lab showed the participants some simple experiments. |
Year(s) Of Engagement Activity | 2018 |